 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 17318-31-9 |
| Molecular formula(MF) | C9H11N5O |
| Molecular Weight(MW): | 205.22 |
| Alias |
| In vitro | DMSO | 41 mg/mL (199.78 mM) |
|---|---|---|
| Water | 41 mg/mL (199.78 mM) | |
| Ethanol | 41 mg/mL (199.78 mM) | |
| In vivo |
| Description | SQ22536 is an inhibitor of adenylyl cyclase with an IC50 of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets. | |
|---|---|---|
| Targets |
|
|
| In vitro |
SQ22536(250 µmol/L) attenuates the inhibitory effect of adenosine against ADP-induced platelet aggregation from 8±5 to 57±5%, respectively (p<0.001). SQ22536 also attenuates an increase of intraplatelet levels of cAMP by adenosine from 29±2 to 9±1 pmol/108 platelets (p<0.05). It has no effect on the platelet antiaggregant activity of inosine (1 to 4 mmol/L) and ADP-induced platelet aggregation[4]. |
|
| In vivo | SQ22536 abolishes the renal protective effects of liraglutide in KK/Ta-Akita mice. the amelioration of glomerular histopathological damage by liraglutide is eliminated in KK/Ta-Akita mice treated with liraglutide in combination with SQ22536. Renal cAMP does not increase after treatment with SQ22536. In a word, the beneficial actions of liraglutide for treatment of nephropathy are inhibited by the adenylate cyclase inhibitor SQ22536[5]. |